EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development
This is an excerpt from a longer report on AI, medicines development and the patent system.
Download the full report here (or by clicking...
Transfer of technology and know-how for the production of pandemic-related health products in the...
A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot
During...
Continuing to ignore the problem of the know-how gap won’t make it go away.
The Covid-19 pandemic was a wake-up call for a variety of issues in access to medicines, one of which was finding a solution to...
Opmerkingen bij de notitie Dwanglicenties van B.J. Bruins, Minister voor Medische Zorg.
Op 15 juni 2018 stuurde Minister Bruins een notitie over dwanglicenties aan de Tweede Kamer. In deze briefing maken wij een aantal voorlopige opmerkingen...
The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless
Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...
Lessons for a pandemic preparedness treaty from previous successes and failures with treaty-based technology...
This post can also be downloaded as a PDF here.
1. Introduction
Scaling-up production of new vaccines to provide many billions of doses on a time-scale...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
The last mile: A few suggestions for the WHO Pandemic Agreement’s last two weeks...
This technical briefing note is also available as a PDF here.
On 16 April, the Bureau of the Intergovernmental Negotiating Body (INB) to draft and...
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...